Replimune Group (NASDAQ:REPL) Trading Down 7.8% – Here’s What Happened

Shares of Replimune Group, Inc. (NASDAQ:REPL) fell 7.8% during trading on Tuesday . The stock traded as low as $7.38 and last traded at $7.3450. 439,765 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 1,292,070 shares. The stock had previously closed at $7.97.

Analyst Upgrades and Downgrades

REPL has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, October 27th. Piper Sandler increased their price target on Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, Wedbush raised their target price on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

Replimune Group Stock Performance

The company has a market cap of $705.97 million, a P/E ratio of -2.49 and a beta of 0.73. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The firm’s fifty day moving average price is $8.35 and its 200-day moving average price is $7.39.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. As a group, research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the sale, the chief executive officer owned 333,576 shares of the company’s stock, valued at $3,712,700.88. This trade represents a 2.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kapil Dhingra sold 3,169 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $10.40, for a total transaction of $32,957.60. Additional details regarding this sale are available in the official SEC disclosure. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Hedge funds have recently modified their holdings of the company. Saturn V Capital Management LP bought a new stake in Replimune Group during the 2nd quarter valued at about $1,198,000. Readystate Asset Management LP boosted its stake in Replimune Group by 1,296.2% in the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after purchasing an additional 2,433,292 shares during the period. Squarepoint Ops LLC grew its holdings in shares of Replimune Group by 394.0% in the second quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after purchasing an additional 54,178 shares in the last quarter. Nan Fung Trinity HK Ltd. purchased a new position in shares of Replimune Group during the 2nd quarter worth about $4,325,000. Finally, Los Angeles Capital Management LLC purchased a new stake in Replimune Group in the 2nd quarter valued at about $403,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.